Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced the initiation of a Phase II clinical study of AK0610, a ...

"ArkBio commences Phase II study of AK0610 for RSV prevention" was originally created and published by Clinical Trials Arena, ...

Study of 2,061 infants reveals RSV, HMPV, influenza, and viral co-infections significantly increase severe lower respiratory ...

Immunizations used to treat COVID-19, respiratory syncytial virus (RSV) and influenza safely reduce the risk of adverse outcomes among people of all ages, according to a systematic analysis of 511 ...

A wave of the highly contagious respiratory syncytial virus is beginning to wash over the United States—sending greater numbers of babies and toddlers to the hospital, recent data show.

Covid-19 infections have been strongly linked with cardiovascular events like a heart disease and stroke, but new research ...

Multiple studies have shown that Covid infection increases the risk of cardiovascular diseases, including heart attack and ...

The official spokesman for the Ministry of Health Dr. Abdullah Al-Sanad announced Wednesday that the increase in respiratory ...

Pfizer has axed 11 programs, including two pipeline assets from its $43 billion Seagen acquisition, work on a ...

"It is well recognized that human papillomavirus (HPV), hepatitis B virus, and other viruses can cause cancer; however, the ...

New study highlights heart attack spike after common viral infections.

A meta-analysis of 511 studies on US COVID-19, respiratory syncytial virus (RSV), and influenza vaccines find meaningful protection against severe disease and hospitalization, evidence that can help ...